Table 1 provides a summary of the common clinical applications of PSMA-targeted ligands and radioactive molecules. With the advancements in clinical research, the development of PSMA-based theranostics has seen a shift from targeting the intracellular domain to targeting the extracellular domain, enabling internalization into viable cancer cells. This targets the limitations of earlier approaches that primarily targeted dying or necrotizing cells for the intracellular domain (56). This evidence concerns the gene FOLH1 and cancer.